Literature DB >> 29484738

Anti-cancer therapy with TNFα and IFNγ: A comprehensive review.

Jing Shen1, Zhangang Xiao1, Qijie Zhao1, Mingxing Li1, Xu Wu1, Lin Zhang2, Wei Hu2, Chi H Cho1,3.   

Abstract

Tumour necrosis factor alpha (TNFα) and interferon gamma (IFNγ) were originally found to be produced by inflammatory cells and play important roles in the immune system and surveillance of tumour growth. By activating distinct signalling pathways of nuclear factor-κB (NF-κB), mitogen-activated protein kinase (MAPK), and JAK/STAT, TNFα and IFNγ were reported to effectively trigger cell death and perform powerful anti-cancer effects. In this review, we will discuss the new advancements of TNFα and IFNγ in anti-cancer therapy.
© 2018 John Wiley & Sons Ltd.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29484738      PMCID： PMC6528874          DOI： 10.1111/cpr.12441

Source DB:  PubMed          Journal:  Cell Prolif        ISSN： 0960-7722            Impact factor:   6.831


  102 in total

1.  Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver.

Authors:  H R Alexander; D L Bartlett; S K Libutti; D L Fraker; T Moser; S A Rosenberg
Journal:  J Clin Oncol       Date:  1998-04       Impact factor: 44.544

2.  Synergistic activation of JNK/SAPK induced by TNF-alpha and IFN-gamma: apoptosis of pancreatic beta-cells via the p53 and ROS pathway.

Authors:  Won Ho Kim; June Woo Lee; Bin Gao; Myeong Ho Jung
Journal:  Cell Signal       Date:  2005-12       Impact factor: 4.315

3.  CD4+ T cell--mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells.

Authors:  Z Qin; T Blankenstein
Journal:  Immunity       Date:  2000-06       Impact factor: 31.745

4.  Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13).

Authors:  F Curnis; A Sacchi; L Borgna; F Magni; A Gasparri; A Corti
Journal:  Nat Biotechnol       Date:  2000-11       Impact factor: 54.908

5.  A phase I trial of recombinant human interferon-gamma in patients with Kaposi's sarcoma and the acquired immunodeficiency syndrome (AIDS).

Authors:  H C Lane; R T Davey; S A Sherwin; H Masur; A H Rook; J F Manischewitz; G V Quinnan; P D Smith; M E Easter; A S Fauci
Journal:  J Clin Immunol       Date:  1989-07       Impact factor: 8.317

6.  Phase II studies of recombinant human interferon gamma in metastatic renal cell carcinoma.

Authors:  J R Quesada; R Kurzrock; S A Sherwin; J U Gutterman
Journal:  J Biol Response Mod       Date:  1987-02

7.  Phase III trial of recombinant interferon gamma in complete responders with small-cell lung cancer.

Authors:  J R Jett; A W Maksymiuk; J Q Su; J A Mailliard; J E Krook; L K Tschetter; C G Kardinal; D I Twito; R Levitt; J B Gerstner
Journal:  J Clin Oncol       Date:  1994-11       Impact factor: 44.544

Review 8.  Efficiency of recombinant human TNF in human cancer therapy.

Authors:  Ferdy J Lejeune; Danielle Liénard; Maurice Matter; Curzio Rüegg
Journal:  Cancer Immun       Date:  2006-03-22

9.  Eastern cooperative group trial of interferon gamma in metastatic melanoma: an innovative study design.

Authors:  J H Schiller; M Pugh; J M Kirkwood; D Karp; M Larson; E Borden
Journal:  Clin Cancer Res       Date:  1996-01       Impact factor: 12.531

10.  Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study.

Authors:  D L Fraker; H R Alexander; M Andrich; S A Rosenberg
Journal:  J Clin Oncol       Date:  1996-02       Impact factor: 44.544
View more
  21 in total

1.  Cytotoxic T Lymphocytes (CTLs) and Kidney Transplantation: An Overview.

Authors:  Federica Rascio; Paola Pontrelli; Giuseppe Grandaliano
Journal:  Methods Mol Biol       Date:  2021

2.  Polysialic Acid Self-assembled Nanocomplexes for Neutrophil-Based Immunotherapy to Suppress Lung Metastasis of Breast Cancer.

Authors:  Chuizhong Fan; Cong Li; Shuang Lu; Xiaoxue Lai; Shuo Wang; Xinrong Liu; Yanzhi Song; Yihui Deng
Journal:  AAPS PharmSciTech       Date:  2022-04-11       Impact factor: 3.246

3.  Alignment of practices for data harmonization across multi-center cell therapy trials: a report from the Consortium for Pediatric Cellular Immunotherapy.

Authors:  Hisham Abdel-Azim; Hema Dave; Kimberly Jordan; Stephanie Rawlings-Rhea; Annie Luong; Ashley L Wilson
Journal:  Cytotherapy       Date:  2021-10-26       Impact factor: 5.414

4.  Thermal stress involved in TRPV2 promotes tumorigenesis through the pathways of HSP70/27 and PI3K/Akt/mTOR in esophageal squamous cell carcinoma.

Authors:  Rongqi Huang; Shuai Li; Chao Tian; Peng Zhou; Huifang Zhao; Wei Xie; Jie Xiao; Ling Wang; Jean de Dieu Habimana; Zuoxian Lin; Yuchen Yang; Na Cheng; Zhiyuan Li
Journal:  Br J Cancer       Date:  2022-07-27       Impact factor: 9.075

5.  Pulmonary Delivery of Nanoparticle-Bound Toll-like Receptor 9 Agonist for the Treatment of Metastatic Lung Cancer.

Authors:  Jillian L Perry; Shaomin Tian; Nisitha Sengottuvel; Emily B Harrison; Balachandra K Gorentla; Chintan H Kapadia; Ning Cheng; J Christopher Luft; Jenny P-Y Ting; Joseph M DeSimone; Chad V Pecot
Journal:  ACS Nano       Date:  2020-06-02       Impact factor: 15.881

Review 6.  Anti-cancer therapy with TNFα and IFNγ: A comprehensive review.

Authors:  Jing Shen; Zhangang Xiao; Qijie Zhao; Mingxing Li; Xu Wu; Lin Zhang; Wei Hu; Chi H Cho
Journal:  Cell Prolif       Date:  2018-02-26       Impact factor: 6.831

7.  Homogeneous polyporus polysaccharide inhibits bladder cancer by polarizing macrophages to M1 subtype in tumor microenvironment.

Authors:  Wenyu Jia; Siwan Luo; Gena Lai; Shiqi Li; Shuai Huo; Meifang Li; Xing Zeng
Journal:  BMC Complement Med Ther       Date:  2021-05-25

8.  AR-negative prostate cancer is vulnerable to loss of JMJD1C demethylase.

Authors:  Yohei Yoshihama; Kyle A LaBella; Eiru Kim; Lori Bertolet; Medina Colic; Jiexi Li; Xiaoying Shang; Chang-Jiun Wu; Denise J Spring; Y Alan Wang; Traver Hart; Ronald A DePinho
Journal:  Proc Natl Acad Sci U S A       Date:  2021-09-07       Impact factor: 11.205

9.  A Novel Redox Modulator Induces a GPX4-Mediated Cell Death That Is Dependent on Iron and Reactive Oxygen Species.

Authors:  Shuai Hu; Mario Sechi; Pankaj Kumar Singh; Lipeng Dai; Sean McCann; Duxin Sun; Mats Ljungman; Nouri Neamati
Journal:  J Med Chem       Date:  2020-08-28       Impact factor: 7.446

10.  Formosanin C promotes the curative efficacy of ultrasound-guided radiofrequency ablation in a mouse model of breast cancer.

Authors:  Zhe Chen; Jing Li; Qianqian Cui; Fuyuan Li; Gaiying Zhang
Journal:  Oncol Lett       Date:  2021-05-24       Impact factor: 2.967
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.